You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Why choose Duac for your patients with mild to moderate inflammatory acne?

The EDF Acne Treatment Guidelines give the highest recommendation for fixed-dose combinations of benzoyl peroxide (BPO) + clindamycin (Duac) or BPO + adapalene as first-line therapy in mild to moderate papulopustular acne. 1 View clinical efficacy and tolerability data for Duac vs alternative treatment approaches to find out why.

Go to Close Top

Web

Duac 5% helps patients to achieve treatment success faster than adapalene/BPO (Epiduo), with favourable tolerability 2

View data

Web

Duac 5% is faster-acting than erythromycin/zinc (Zineryt), with comparable tolerability 3

View data

Web

Duac 5% is more effective than monotherapies* in reducing inflammatory lesions, with comparable tolerability 4 5

View data

Web

The EDF Acne Treatment Guidelines give the highest recommendation for fixed-dose combinations of benzoyl peroxide (BPO) + clindamycin (Duac) or BPO + adapalene as first-line therapy in mild to moderate papulopustular acne. 1

View guidelines

Find out more about how Duac works

View MOA

* monotherapies including adapalene, BPO and clindamycin

References:

  1. Nast A et al. JEADV 2016;30(8):1261–1268.
  2. Zouboulis C et al. Cutis 2009;84:223–229.
  3. Langner A et al. JEADV 2007;21:311–319.
  4. Lookingbill DP et al. J Am Acad Dermatol 1997;37:590–595.
  5. Langner A et al. Br J Dermatol 2008;158:122–129.
  6. Eichenfield LF et al. J Drugs Dermatol 2011;10:1382–1396.
  7. Schaller M et al. J Eur Acad Dermatol Venereol 2016;30:966–973.

Duac is a registered trademark of the GlaxoSmithKline group of companies.